Financiere de Tubize SA
FTD
Company Profile
Business description
Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a world-wide biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. Majority of its sales revenue is derived from its neurology products, followed by its immunology products. The company's plan focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.
Contact
Allee de la Recherche, 60
Brussels1070
BELT: +32 497515208
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
250
Stocks News & Analysis
stocks
This might be the best core stock bargain in the US market today
Patient investors should consider building a position in this wide-moat stock while it’s seriously undervalued.
stocks
Data center demand drives strong earnings outlook for SGM
Sims guides huge earnings upgrade as data center metals demand spikes.
stocks
Chart of the Week: AI proving a threat to company moats
The latest insights on AI from our equity research team.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,628.30 | 34.80 | -0.40% |
| CAC 40 | 7,665.62 | 142.25 | -1.82% |
| DAX 40 | 22,380.19 | 459.37 | -2.01% |
| Dow JONES (US) | 45,577.47 | 443.96 | -0.96% |
| FTSE 100 | 9,918.33 | 145.17 | -1.44% |
| HKSE | 25,277.32 | 223.26 | -0.88% |
| NASDAQ | 21,647.61 | 443.08 | -2.01% |
| Nikkei 225 | 53,372.53 | 1,866.87 | -3.38% |
| NZX 50 Index | 12,989.99 | 61.62 | -0.47% |
| S&P 500 | 6,506.48 | 100.01 | -1.51% |
| S&P/ASX 200 | 8,428.40 | 43.90 | -0.52% |
| SSE Composite Index | 3,957.05 | 49.50 | -1.24% |